BIOMAT Database Logo BIOMAT Database Logo

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells. 2020

Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
School of Medical Instrument and Food Engineering, 47863University of Shanghai for Science and Technology, China.

Chimeric antigen receptor (CAR) T-cell immunotherapy still faces many challenges in the treatment of solid tumors, one of which is T-cell dysfunction or exhaustion. Immunomodulator lenalidomide may improve CAR T-cell function. In this study, the effects of lenalidomide on CAR T-cell functions (cytotoxicity, cytokine secretion, and cell proliferation) were investigated. Two different CAR T cells (CD133-specific CAR and HER2-specific CAR) were prepared, and the corresponding target cells including human glioma cell line U251 CD133-OE that overexpress CD133 and human breast cancer cell line MDA-MB-453 were used for functional assay. We found that lenalidomide promoted the killing of U251 CD133-OE by CD133-CAR T cells, the cytokine secretion, and the proliferation of CD133-CAR T cells. Lenalidomide also enhanced the cytotoxicity against MDA-MB-453 and the cytokine secretion of HER2-CAR T cells but did not affect their proliferation significantly. Furthermore, lenalidomide may regulate the function of CAR T cells by inducing the degradation of transcription factors Ikaros and Aiolos.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076962 Receptors, Chimeric Antigen Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens. Chimeric Antigen Receptor,Chimeric T-Cell Receptor,Artificial T-Cell Receptors,Chimeric Antigen Receptors,Chimeric Immunoreceptors,Chimeric T-Cell Receptors,Antigen Receptor, Chimeric,Antigen Receptors, Chimeric,Artificial T Cell Receptors,Chimeric T Cell Receptor,Chimeric T Cell Receptors,Immunoreceptors, Chimeric,Receptor, Chimeric Antigen,Receptor, Chimeric T-Cell,Receptors, Artificial T-Cell,Receptors, Chimeric T-Cell,T-Cell Receptor, Chimeric,T-Cell Receptors, Artificial,T-Cell Receptors, Chimeric
D000077269 Lenalidomide A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-,3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,CC 5013,CC-5013,CC5013,IMiD3 Cpd,Revimid,Revlimid
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018929 Cell Culture Techniques Methods for maintaining or growing CELLS in vitro. Cell Culture,Cell Culture Technique,Cell Cultures,Culture Technique, Cell,Culture Techniques, Cell
D020533 Angiogenesis Inhibitors Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. Angiogenesis Factor Inhibitor,Angiogenesis Inhibitor,Angiogenetic Antagonist,Angiogenetic Inhibitor,Angiogenic Antagonist,Angiogenic Antagonists,Angiogenic Inhibitor,Angiostatic Agent,Angiostatic Agents,Anti-Angiogenetic Agent,Anti-Angiogenic Drug,Anti-Angiogenic Drugs,Antiangiogenic Agent,Neovascularization Inhibitor,Neovascularization Inhibitors,Angiogenesis Factor Inhibitors,Angiogenetic Antagonists,Angiogenetic Inhibitors,Angiogenic Inhibitors,Antagonists, Angiogenic,Anti-Angiogenesis Effect,Anti-Angiogenesis Effects,Anti-Angiogenetic Agents,Antiangiogenesis Effect,Antiangiogenesis Effects,Antiangiogenic Agents,Inhibitors, Angiogenesis,Inhibitors, Angiogenetic,Inhibitors, Angiogenic,Inhibitors, Neovascularization,Agent, Angiostatic,Agent, Anti-Angiogenetic,Agent, Antiangiogenic,Agents, Angiostatic,Agents, Anti-Angiogenetic,Agents, Antiangiogenic,Antagonist, Angiogenetic,Antagonist, Angiogenic,Antagonists, Angiogenetic,Anti Angiogenesis Effect,Anti Angiogenesis Effects,Anti Angiogenetic Agent,Anti Angiogenetic Agents,Anti Angiogenic Drug,Anti Angiogenic Drugs,Drug, Anti-Angiogenic,Drugs, Anti-Angiogenic,Effect, Anti-Angiogenesis,Effect, Antiangiogenesis,Effects, Anti-Angiogenesis,Effects, Antiangiogenesis,Factor Inhibitor, Angiogenesis,Factor Inhibitors, Angiogenesis,Inhibitor, Angiogenesis,Inhibitor, Angiogenesis Factor,Inhibitor, Angiogenetic,Inhibitor, Angiogenic,Inhibitor, Neovascularization,Inhibitors, Angiogenesis Factor

Related Publications

Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.
January 2023, Theranostics,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.
October 2023, Heliyon,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
CAR T Cell Membrane Camouflaged Nanocatalyst Augments CAR T Cell Therapy Efficacy Against Solid Tumor.
May 2024, Small (Weinheim an der Bergstrasse, Germany),
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
July 2022, Leukemia & lymphoma,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Driving CAR T Cells against Solid Tumors.
July 2022, Cancer discovery,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
June 2019, Cell death & disease,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity.
November 2022, Cancer immunology research,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
April 2020, Cell death & disease,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
CAR T Cell Locomotion in Solid Tumor Microenvironment.
June 2022, Cells,
Zhixiong Wang, and Guomin Zhou, and Na Risu, and Jiayu Fu, and Yan Zou, and Jiaxing Tang, and Long Li, and Hui Liu, and Qian Liu, and Xuekai Zhu
Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
January 2022, International review of cell and molecular biology,
Copied contents to your clipboard!